Results 71 to 80 of about 21,108 (240)

Dapagliflozin and Sirtuin-1 interaction and mechanism for ameliorating atrial fibrillation in a streptozotocin-induced rodent diabetic model

Biomolecules & Biomedicine
The incidence of atrial fibrillation (AF) increases with age and is particularly high in individuals with diabetes. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), such as dapagliflozin, show promise in treating heart failure (HF) and reducing the ...
Wei-Chieh Lee, Yu-Wen Lin, Jhih-Yuan Shih, Zhih-Cherng Chen, Nan-Chun Wu, Wei-Ting Chang, Ping-Yen Liu   +6 more
doaj   +1 more source

Role of Dapagliflozin in Protection of Contrast Induced Nephropathy in Patients Eligible for Angiographic Procedures [PDF]

Zagazig University Medical Journal
Background: Dapagliflozin has proved great effects extend beyond glycemic control, including reduction in cardiovascular events, kidney disease progression, and mortality.
Asmaa kenawy, Rehab Yaseen, Walaa farid, Eslam El Habashy   +3 more
doaj   +1 more source

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors

Frontiers in Pharmacology, 2021
This study compared dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and dipeptidyl peptidase-4 inhibitors (DPP-4i) with regard to cardiovascular (CV) event incidence and direct medical costs during type 2 diabetes treatment.
Jong-Mi Seong, Jong Joo Kim, Hae Jin Kim, Hyun Soon Sohn   +3 more
doaj   +1 more source

Model‐Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model‐Based Longitudinal HbA1c Meta‐Analysis from EMA Marketing Authorization Applications

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence generation for antihyperglycemic therapies in pediatric type 2 diabetes mellitus (T2DM) remains challenging, with most randomized trials failing to demonstrate statistically significant reductions in glycated hemoglobin (HbA1c), partly due to substantial between‐subject variability.
Pieter J. Colin, Efthymios Manolis, Jeroen V. Koomen   +2 more
wiley   +1 more source

Effect of sodium-glucose co-transporter 2 inhibitor on contrast-induced acute kidney injury and prognosis in type 2 diabetes patients undergoing percutaneous coronary intervention

Frontiers in Medicine
IntroductionContrast-induced acute kidney injury (CIAKI) is a common and serious complication following contrast administration in patients undergoing percutaneous coronary intervention (PCI).
Shicheng Yang, Huifang Hao, Xiufeng Zhai, Peng Zhang, Naikuan Fu   +4 more
doaj   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah, Junsung Nam, Jung Wook Youn, Yun Mi Yu, Soyoung Kang   +4 more
wiley   +1 more source

The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study

BMC Cardiovascular Disorders
Objective To evaluate the effect of dapagliflozin on cardiorespiratory fitness (CRF) in patients with coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM) following percutaneous coronary intervention (PCI).
Jiali Yang, Xinru Li, Liangqiu Tang, Wenmao Fan, Aihua Li, Wanming Zhou, Jungang Pang, Qiuxiao Yuan, Ming Zhong, Jinhui Hou, Lan Wang, Wenjiao Liao, Xiangyang Liu   +12 more
doaj   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan

Kidney International Reports
Introduction: Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays the progression of chronic kidney disease (CKD), its effect on patients with autosomal dominant polycystic kidney disease (ADPKD) has not been established ...
Kiyotaka Uchiyama, Daisuke Kamano, Tomoki Nagasaka, Eriko Yoshida Hama, Ryoichi Shirai, Rena Sumura, Ei Kusahana, Akane Yanai, Takashin Nakayama, Takahide Kimura, Rina Takahashi, Takahiro Kasai, Takaya Tajima, Koji Hosoya, Tatsuhiko Azegami, Shintaro Yamaguchi, Jun Yoshino, Jun Ito, Matsuhiko Hayashi, Takeshi Kanda, Yoshitaka Ishibashi, Naoki Washida, Hiroshi Itoh, Kaori Hayashi   +23 more
doaj   +1 more source

Effects of dapagliflozin on HIF1 in HK2 cells.

, 2016
(A) Representative Western blot: dapagliflozin increased HIF1 expression and phosphorylation of AMPK and ERK in hypoxic HK2 cells. *P 0.05 vs., dapagliflozin nontreated normoxic HK2 cells, #P 0.05 vs. normoxic HK2 cells. **P 0.05 vs.
Jin Young Jeong (425020), Ki-Ryang Na (3155670), Kang Wook Lee (3155664), Yoon-Kyung Chang (3155658), Hyunsu Choi (3155667), Dae Eun Choi (3155661), Beom Jin Lim (316728)   +6 more
core   +1 more source